INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 914 | $547.45 | 527,795 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 7,197 | $476.51 | 528,214 |
| Dec 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 3,038 | $546.36 | 528,709 |
| May 14, 2010 |
Director
Trans History: 742
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 2,600 | $26.96 | 528,751 |
| May 12, 2020 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Open market or private sale of non-derivative or derivative security | 20,267 | $570.49 | 528,991 |
| May 14, 2010 |
Director
Trans History: 742
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 17,400 | $27.19 | 531,351 |
| Dec 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 5,611 | $545.51 | 531,747 |
| May 11, 2020 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 64,631 | $571.43 | 534,868 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 4,223 | $475.43 | 535,411 |
| Dec 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 4,290 | $544.52 | 537,358 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.